Chimerix granted stock options to new employees, focused on developing medicines for deadly diseases.

From GlobeNewswire: 2024-12-06 16:01:00

Chimerix granted inducement awards to three new employees in the form of non-statutory stock options totaling 385,000 shares. These options have a 10-year term and will vest over four years. The company’s mission is to develop medicines for deadly diseases, with a focus on ONC201 for H3 K27M-mutant glioma. Chimerix is also conducting Phase 1 studies on ONC206 for safety and PK data. For more information, contact Will O’Connor at Stern Investor Relations at 212-362-1200 or [email protected].



Read more at GlobeNewswire: Chimerix Reports Inducement Grants Under Nasdaq Listing